Megan Sutton, Dnp, Acnp Bc
About Megan Sutton, Dnp, Acnp Bc
Megan Sutton, DNP, ACNP-BC, is the Medical Strategy lead for Cardiomyopathies at Bristol Myers Squibb, with extensive experience in medical affairs and research.
Company
Megan Sutton is currently employed at Bristol Myers Squibb. Her role focuses on Medical Strategy for Cardiomyopathies within US Medical Affairs. She has previous experience with the same company as a Medical Lead for Cardiomyopathies under US Health Economics and Outcomes Research.
Title
Megan Sutton holds the title of Medical Strategy for Cardiomyopathies in US Medical Affairs at Bristol Myers Squibb. Her responsibilities include providing clinical subject matter expertise, guiding strategic directions for Real-World Evidence (RWE), and collaborating with other medical functions on scientific communication strategies.
Education and Expertise
Megan Sutton has an extensive educational background in nursing. She earned her Doctor of Nursing Practice (DNP) from The George Washington University. She also holds a Master of Science in Nursing (MSN) from Columbia University in New York City and a Bachelor of Science in Nursing (BSN) from Georgetown University. Her expertise spans cardiac surgery, cardiomyopathies, emergency care, and health outcomes research.
Professional Background
Megan Sutton's professional experience is diverse and spans many roles in the healthcare sector. She has worked as a Medical Science Liaison for Novartis in both Chicago and Boston, focusing on the cardiovascular team. She also served as a Global Telehealth Nurse Practitioner for AXA Assistance USA, a Medical Scientific Liaison for Portola Pharmaceuticals, and a Sr. Regional Medical Lead for MyoKardia. Earlier in her career, she held nursing roles in various prestigious institutions, such as University of Chicago Medical Center and New York-Presbyterian Hospital.
Achievements
Megan Sutton has led the data gap analysis and strategy for US-relevant data generation for mavacamten, a first-in-class therapeutic agent for obstructive hypertrophic cardiomyopathy. She contributes to the strategic planning for market access projects and plays a crucial role in the development and implementation of the US medical strategy to support the launch of new therapeutic agents, including mavacamten.